若生智能
Drug Database
DO

doxorubicin hydrochloride (Libod / Libaoduo)

✓ Approved

Shanghai Fudan-Zhangjiang · TOP2A · 小分子

什么是 doxorubicin hydrochloride？

doxorubicin hydrochloride 是一种小分子，由Shanghai Fudan-Zhangjiang研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Libod, Libaoduo
公司Shanghai Fudan-Zhangjiang
药物类别小分子
分子靶点TOP2A
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Shanghai Fudan-Zhangjiang

作用机制

分子靶点

doxorubicin hydrochloride 作用于 1 个分子靶点：

TOP2ADNA topoisomerase II alpha (TOP2alpha, TOPIIA)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

doxorubicin hydrochloride 针对 4 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Kaposi's sarcoma✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Ovarian cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Plasma cell myeloma✓ Approved

相关研究文献

PubMedACS nano2026-07-27

Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines.

Pan Feng F, Xu Qingyuan Q, Tian Kaisong K, Luo Gan G et al.

Clinical translation of nanomedicines is greatly hindered by insufficient understanding of their in vivo process, yet a key challenge lies in quantifying the encapsulated versus free drug forms in tissues and cells. Herein, we present a facile, versatile anti-PEG single-chain variable-fragment antibody (PEG-scFv)-based method enabling quantitative measurement of both forms in various biofluids (e.g., interstitial fluid, cytoplasm). By this method, we map the in vivo process of PEGylated liposomal doxorubicin (sLip/Dox) at unprecedented resolution. In the bloodstream, doxorubicin remains largely encapsulated in liposomes (>99%). In liver as the main organ for drug elimination, less drug was distributed in the interstitium (>80% encapsulated) but more in liver cells (mainly in Kupffer cells) released in a time-dependent manner, accompanying doxorubicin transferred to hepatocytes most in free form by 12 h postinjection. After extravasation into tumors, there was a limited access of sLip/Dox to tumor cells, confining most of the drug in the interstitium mainly being encapsulated (more than 75%), and the internalized fraction underwent a gradual release process in both tumor-associated macrophages and tumor cells. These findings revealed that for sLip/Dox, which primarily underwent drug release intracellularly, cellular internalization rates could be the key factor in determining its in vivo performance. Given widespread PEGylation on developing nanomedicines and the cost-effectiveness of scFv production, PEG-scFv offers a broadly applicable tool for dissecting in vivo processes of nanomedicines to establish dose-effect relationships like small-molecule drugs, further to guide rational nanotherapeutic design.

PMID 42503863
阅读全文 →
PubMedGels (Basel, Switzerland)2026-07-27

Development, Characterization, and In Vitro Hemostatic Assessment of an Alginate-Based Wound Dressing Incorporating Liposomal Curcumin.

Nagy Florina Antonela-Loredana FA, Mihaly Cozmuta Leonard L, Marcus Melisa M, Mihalescu Beatrice B et al.

Exuding wounds require dressings that combine effective exudate management, hemostatic activity, and bioactive therapeutic effects. Curcumin possesses antioxidant and anti-inflammatory properties, but its clinical application is limited by poor bioavailability and uncertain effects on coagulation. This study aimed to develop an alginate-based dressing incorporating liposomal curcumin and evaluate its physicochemical and in vitro hemostatic properties. Alginate dressings containing 0-0.5% liposomal curcumin were prepared and characterized. The selected 0.2% liposomal curcumin (D_0.2) formulations were evaluated for swelling behavior, dimensional stability, water vapor transmission rate, optical properties, calcium and polyphenol release, prothrombin time, fibrin morphology, and fibrin secondary structure in simulated serous, inflammatory, and infected wound exudates. D_0.2 exhibited favorable macroscopic integrity and flexibility, enhanced swelling capacity, improved exudate management, and favorable moisture-vapor permeability. The dressing showed controlled release of Ca2+ and polyphenols, producing a biphasic hemostatic response characterized by transient early coagulation delay followed by accelerated clot formation. Fibrin analysis revealed improved network organization and preservation of ordered protein conformations, particularly under inflammatory and infected conditions. Liposomal curcumin-modified alginate dressings combine effective fluid handling with adaptive hemostatic performance and enhanced fibrin stabilization, demonstrating promising potential for the management of serous, inflammatory, and infected wounds.

PMID 42505308
阅读全文 →
PubMedBiomedical chromatography : BMC2026-07-27

Characterization of Liposomal and Free Aqueous Extracts of Ceratonia siliqua: Evaluation of Phenolic Contents and Antimicrobial, Antimutagenic, Enzyme Inhibitory, and Antiproliferative Activities.

Macit Caglar C, Macit Meltem M, Eyupoglu Ozan Emre OE, Ozer Elcin Ezgi EE et al.

Ceratonia siliqua (carob) is a Mediterranean medicinal plant rich in phenolic contents but limited by poor bioavailability. To address this, an aqueous carob extract was formulated into liposomes and characterized. Phenolic profiles of the free (CBE) and the liposomal extracts (LCBE) were compared by the HPLC. Genotoxic safety and biological activities of both extracts were evaluated. HPLC analysis identified key phenolic acids in both formulations; while the concentration of gallic acid was determined as 23.5 ppm in CBE and 18.5 ppm in LCBE, caffeic acid levels were determined as 43.5 ppm in CBE and 24.5 ppm in LCBE. In addition, protocatechuic acid followed a similar trend, with concentrations of 55.1 ppm in CBE and 35.1 ppm in LCBE. Biologically, the LCBE showed enhanced antibacterial activity, particularly against Escherichia coli. The LCBE demonstrated stronger competitive inhibition of AChE and α-amylase when compared with the free extract, suggesting potential relevance for enzyme-modulating and glycemic support. In preliminary MTT-based cell viability screening, LCBE showed relatively greater activity than CBE in MCF-7 cells; however, this effect was weak, while PC-3 and MDA-MB-231 cells showed limited responsiveness under the tested conditions. Further selectivity and mechanistic studies should be done in vivo bioavailability/pharmacokinetics.

PMID 42503596
阅读全文 →
PubMedSignal transduction and targeted therapy2026-07-27

Bacteria-mimicking cancer cells reprogram macrophages via multiple pattern recognition receptor pathways for cancer immunotherapy.

Song Seoyoon S, Yu Dongjun D, Kang Haneul H, Lee Deborah D et al.

Although macrophages are a powerful cell-based platform for cancer immunotherapy, their antitumor functions, such as phagocytosis and inflammatory responses, are limited by the immunosuppressive tumor microenvironment. Here, we show that decorating cancer cell membranes with bacteria-derived pathogen-associated molecular patterns (PAMPs) initiates phagocytosis and inflammatory responses of macrophages toward cancer cells involving various pattern-recognition receptor signaling pathways. Bacteria-derived PAMPs were formulated into membrane-decorating nanoparticles, and these nanoparticles reprogrammed immunosuppressive macrophages into inflammatory phenotypes. Cancer cell membrane-attached PAMP nanoparticles maintained their immunostimulatory responses, stimulating macrophages' antitumor functions. The fraction of phagocytic macrophages significantly increased when coincubated with membrane-decorated cancer cells, along with an increased secretion of inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Transcriptomic gene ontology analysis revealed that the response of macrophages to PAMP-decorated cancer cells resembled their response to bacteria, involving signaling pathways including inflammatory response and innate immune response. In a mouse model, locally injected membrane-decorating PAMP nanoparticles suppressed tumor growth. The therapeutic effect was more pronounced in combination with the chemotherapeutic drug doxorubicin. Median survival days significantly increased in both the PAMP nanoparticle and the PAMP nanoparticle plus doxorubicin combination group with complete remission cases, compared to the doxorubicin group. Our findings provide insights into the use of macrophages as a cancer immunotherapy modality.

PMID 42503515
阅读全文 →
PubMedAnnals of medicine2026-07-27

Liposomal bupivacaine versus ropivacaine for surgical site infiltration in lumbar fusion: a prospective randomized controlled trial.

Yue Feng F, Zhai Wenwen W, Lyu Yanhan Y, Qi Qiang Q et al.

Effective postoperative pain control after lumbar spine surgery remains challenging, and excessive opioid use is associated with adverse outcomes. Evidence comparing liposomal bupivacaine (LB) with conventional long-acting local anesthetics in spine surgery is limited. In this single-center, prospective, randomized, patient- and outcome assessor-blinded trial, adult undergoing one- or two-level posterior lumbar decompression and fusion were assigned (1:1) to surgical site infiltration with either LB (266 mg) plus 25 mg plain bupivacaine (LB group) or ropivacaine (R group). The primary outcome was 72 h cumulative opioid consumption (morphine milligram equivalents, MME). Secondary outcomes included time-profile opioid consumption, pain scores, rescue analgesia, safety, and functional recovery. A total of 202 patients were included in the modified intention-to-treat analysis. Cumulative MME within 72 h was significantly lower in the LB group compared with the R group [43.0 (37.0, 58.0) mg vs. 58.0 (46.0, 73.0) mg], corresponding to a 22% relative reduction (GMR 0.78, 95% CI 0.71-0.85; p < 0.001). The reduction was most pronounced during 8-24 h and 24-48 h postoperatively. Overall pain scores at rest and with movement, as well as 72-h pain AUC, were lower in the LB group. No significant between-group differences were observed in rescue analgesia, adverse events and functional recovery. In patients undergoing one- or two-level posterior lumbar decompression and fusion, surgical site infiltration with an LB-based combined regimen, compared with ropivacaine monotherapy, reduced 72-h opioid consumption and cumulative postoperative pain burden without an observed increase in adverse events or impairment of early functional recovery.

PMID 42504098
阅读全文 →
PubMedJournal of fungi (Basel, Switzerland)2026-07-27

Non-Interventional, Retrospective, Multicenter Study on the Renal Safety of Liposomal Amphotericin B in Critically Ill Patients with Invasive Pulmonary Aspergillosis.

Suberviola Borja B, Ceballos Jose Peral Gutierrez de JPG, Martin Maria Jose Asensio MJA, Soriano Cuesta Cruz C et al.

Purpose: This study aims to determine the incidence of kidney injury associated with liposomal amphotericin B (L-AmB) treatment, based on RIFLE criteria, in patients admitted to the intensive care unit (ICU) with invasive pulmonary aspergillosis (IPA). Materials and Methods: A retrospective, multicenter observational study including patients treated with L-AmB for IPA while admitted to the ICU between 1 January 2015, and 31 December 2022. Results: A total of 65 patients were included. The prevalence of renal failure was 35.39%. Renal failure was mostly mild and reversible. The need for major surgery (OR 6.71; p = 0.121) and concomitant use of other nephrotoxic treatments (OR 2.5; p = 0.194) emerged as potential risk factors for the development of renal failure; however, neither association reached statistical significance. Overall mortality was 66.2%, significantly higher in the group with renal failure (82.6% vs. 57.1%; p = 0.03). Factors associated with mortality included concomitant use of other nephrotoxic agents (OR 4.51; p = 0.024) and development of renal failure (OR 3.66; p = 0.068). Duration of L-AmB treatment was not associated with mortality. Regarding creatinine recovery, all patients who developed renal failure but survived showed creatinine levels below 1.5 mg/dL after completion of treatment. Conclusions: Renal impairment was common in this high-risk population of critically ill patients, with renal function impairment in one-third of exposed patients, although most cases were mild. In this population, concomitant administration of other nephrotoxic drugs was associated with both renal failure and mortality. Treatment duration with L-AmB was not linked to mortality, and creatinine levels normalized after therapy completion.

PMID 42506220
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多doxorubicin hydrochloride